Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VivoSim Labs, INC.VIVS · Entity 8386 | Chief Commercial Officer | August 31, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VivoSim Labs, INC.
Report date August 31, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Purchase · Acquired 10,000 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 1, 2026 20:01 UTC | VivoSim Labs, INC. VIVS · Entity 8386 | PurchaseCommon Stock | 10,000 | $0.28 | $2,804.00 |
DisclosureSEC source: 0001193125-26-378358 · ownership.xml · nonDerivative · entry 1 Lialin Tony Serge · CIK 0002082194 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 11, 2025 Filed Aug 22, 2025 00:45 UTC | VivoSim Labs, INC. VIVS · Entity 8386 | GrantOptions (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000950170-25-110771 · ownership.xml · derivative · entry 1 Lialin Tony Serge · CIK 0002082194 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-08-11 F1 · derivative.exercise_date: The option vests over a four year period, with 25% of the total number of shares subject to the option vesting on the August 11, 2026, and the balance vesting in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.